Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Gefapixant Formulations and Omeprazole Interaction
NCT02790840Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- May 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gefapixant in chronic cough, sponsored by Merck & Co. Primary endpoints: Maximum Plasma Concentration at 12 hours and Maximum Plasma Concentration with Omeprazole at 12 hours. Started May 2016; status: completed.
02
Drugs
gefapixant
03
Conditions
chronic cough
Beyond the preview
Go deeper on NCT02790840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02790840.